Conversely, in human ovarian cancer cells, increased DNA methylation on the NFE2L2 promoter by the combined administration of trastuzumab and pertuzumab inhibited the expression of NRF2 and weakened its antioxidant function to perform an anti-cancer effect (21). Here, NFE2L2 is linked to ovarian carcinoma.